Pulmonary Actinomycosis and Mucormycosis Coinfection in a Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia Undergoing Chemotherapy. Issue 2 (26th March 2022)

• Record Type: Journal Article
• Authors: Fujisaki, Toru; Inagaki, Jiro; Kouroki, Masahiko; Honda, Yuko; Matsuishi, Toshiya; Kamizono, Junji; Yasui, Masahiro
• Is Part Of: Journal of pediatric hematology/oncology. Volume 44:Issue 2(2022)
• Page Start: e529
• Page End: e531
• Publication Date: 2022-03-26
• Subjects: pulmonary actinomycosis -- pulmonary mucormycosis -- immunocompromised patient -- surgical resection -- histopathology; Pediatric hematology -- Periodicals; Tumors in children -- Periodicals; 618.9215
• DOI: 10.1097/MPH.0000000000002181
• Languages: English
• ISSNs: 1077-4114

Abstract

Abstract : Mucormycosis is an opportunistic and progressive infection, while actinomycosis usually grows gradually and rarely develops in immunocompromised patients. Here we report a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia who developed a pulmonary actinomycosis and mucormycosis coinfection. Once the diagnosis of actinomycosis was confirmed by bronchoscopy, lobectomy performed before stem cell transplantation revealed mucormycosis. The patient successfully underwent transplantation using a therapeutic antifungal agent for mucormycosis. When an immunocompromised patient develops an infection of unknown etiology, physicians should consider these pathogens as the possible cause. In addition, surgical intervention should be considered as an important treatment option.